Aclexa 200 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aclexa 200 mg trde kapsule

krka, d.d., novo mesto - celekoksib - kapsula, trda - celekoksib 200 mg / 1 kapsula - celekoksib

Aclexa 100 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aclexa 100 mg trde kapsule

krka, d.d., novo mesto - celekoksib - kapsula, trda - celekoksib 100 mg / 1 kapsula - celekoksib

Aclexa 100 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aclexa 100 mg trde kapsule

krka, d.d., novo mesto - celekoksib - kapsula, trda - celekoksib 100 mg / 1 kapsula - celekoksib

Aclexa 200 mg trde kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

aclexa 200 mg trde kapsule

krka, d.d., novo mesto - celekoksib - kapsula, trda - celekoksib 200 mg / 1 kapsula - celekoksib

Darzalex Evropska unija - slovenščina - EMA (European Medicines Agency)

darzalex

janssen-cilag international n.v. - daratumumab - multiple myeloma - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. v kombinaciji z bortezomib, thalidomide in dexamethasone za zdravljenje odraslih bolnikov z na novo prijavljenih več plazmocitom, ki so upravičeni do autologous matičnih celic za presajanje. v kombinaciji z lenalidomide in dexamethasone, ali bortezomib in dexamethasone, za zdravljenje odraslih bolnikov z več plazmocitom, ki so prejeli vsaj en pred terapijo. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. kot monotherapy za zdravljenje odraslih bolnikov z relapsed in ognjevzdržne več plazmocitom, katerih predhodno zdravljenje vključeni proteasome serotonina in imunomodulatornimi agent in ki so pokazali napredovanja bolezni na zadnji terapija. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.